<DOC>
	<DOCNO>NCT01921790</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety avastin combine gemcitabine , oxaliplatin , pegaspargase dexamethasone ( Avastin+ GemAOD ) first-line treatment patient untreated natural killer ( NK ) /T cell lymphoma</brief_summary>
	<brief_title>Avastin+ GemAOD As First-Line Treatment NK/T Cell Lymphoma</brief_title>
	<detailed_description>Recent study show vascular endothelial growth factor ( VEGF ) associate poor outcome patient Non-Hodgkin 's Lymphoma , Avastin impact tumor endothelial cell make standard chemotherapy work well T cell lymphoma . Many research Gemcitabine combine Oxaliplatin treatment recurrent refractory Non-Hodgkin 's lymphoma show patient could benefit combination treatment . Pegaspargase play important role treatment NK/T cell lymphoma . Dexamethasone use combination agent treatment lymphoma may implicate development growth cancers.So explore evaluate efficacy safety Avastin combine gemcitabine , oxaliplatin , pegaspargase dexamethasone ( Avastin+ GemAOD ) first-line treatment patient untreated NK/T cell lymphoma</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>Histologic diagnosis NK/T Cell Lymphoma ; Age:1880 year ; Eastern Cooperative Oncology Group ( ECOG ) status 03 , Estimated survival time &gt; 3 month ; Normal haematological , liver renal function ( WBC count≥4×109/L , Hemoglobin≥100g/L , platelet count≥100×109/L , bilirubin＜1.5×ULN , Alanine transaminase ( ALT ) Aspartate Aminotransferase ( AST ) ＜2.5×ULN , serum creatinine＜1.5×ULN ) , normal coagulation function cardiac function ; Appreciable measurable lesion ; No history malignancy ; No previous treatment include chemotherapy , radiotherapy , target therapy stem cell transplantation ; No serious disease conflict treatment present trial ; No concurrent treatment conflict treatment present trial ( include steroid drug ) ; Voluntary participation sign informed consent . The patient condition : clinically significant ventricular tachycardia ( VT ) , atrial fibrillation ( AF ) , heart block , myocardial infarction ( MI ) , congestive heart failure ( CHF ) , symptomatic coronary artery heart disease require medication ; The patient suffer organ transplant The patient participate clinical trial within 30 day enrollment participate clinical study ; The patient active bleed new thrombotic disease , take anticoagulant drug history bleeding tendency ; The patient suffer surgery less four week , less six week ; The patient major vascular invasion ; The patient abnormal liver function ( total bilirubin &gt; 1.5 time normal value , ALT / AST &gt; 2.5 time normal ) , abnormal renal function ( serum creatinine &gt; 1.5 time normal ) , blood abnormality ( absolute neutrophil count &lt; 1.5 × 109 / L , platelets &lt; 80 × 109 / L , hemoglobin &lt; 90g /L ) ; The patient moderate severe proteinuria ; Severe hypertension , BP≥160/100mmHg ; The patient mentally ill / unable obtain informed consent ; The patient drug addiction , alcohol abuse affect longterm evaluation test result ; The patient pregnancy , lactation woman childbearing age want take contraceptive measure subject ; Clinical laboratory support brain metastasis ; The patient history allergy test drug ; The patient suitable participate investigator judge researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Avastin+ GemAOD</keyword>
	<keyword>first line chemotherapy</keyword>
	<keyword>NK/T-cell Lymphoma</keyword>
</DOC>